Cancer is one of the leading causes of morbidity and mortality worldwide. As the world's population is changing in both size and age composition, the number of new cancer cases is expected to rise significantly over the next decades. Factors such as expanded development of new cancer therapies, long-term pharmacological treatment and increased survival due to improved care which can cause increased long term side effects urge more research in the field of cancer pharmacoepidemiology.
Cancer pharmacoepidemiology at CPE includes all research to investigate the effects of medications on cancer risk, response to cancer treatments, and any adverse or long-term effects of pharmacologic agents used to treat cancer.
As large sample sizes are necessary to assure detection of cancer as side effect of different treatment regimens or investigate side effects of cancer drugs many of our studies are international collaborative projects. Some examples of our studies in this field are investigating exposure to antidiabetic agents and risk of bladder cancer, side effects of lung cancer treatments, and risk of breast cancer among patients exposed to antipsychotics.
The research area is led by Shahram Bahmanyar (Publications on PubMed)